Pneumonectomy After Chemoradiation Therapy for Non-Small Cell Lung Cancer: Does “Side” Really Matter? Anthony W. Kim, MD, L. Penfield Faber, MD, William.

Slides:

Advertisements

Similar presentations

Thomas W. Rice, MD, Deepak Khuntia, MD, Lisa A. Rybicki, MS, David J

Advertisements

Jeffrey M. Griffin, MD, MS, Carolyn E. Reed, MD, Chadrick E

Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients Benjamin T. Gielda, MD,

Usman Ahmad, MD, Zuoheng Wang, PhD, Ayesha S

Elizabeth A. David, MD, David T

Jeffrey L. Port, MD, Robert J. Korst, MD, Paul C. Lee, MD, Amanda L

Definitive or Preoperative Chemoradiation Therapy for Esophageal Cancer: Patterns of Care and Survival Outcomes Meng S. Shao, MD, Andrew T. Wong, MD,

Complete Thoracic Mediastinal Lymphadenectomy Leads to a Higher Rate of Pathologically Proven N2 Disease in Patients With Non-Small Cell Lung Cancer

Preoperative Serum Fibrinogen Level Predicts Postoperative Pulmonary Complications After Lung Cancer Resection Suk-Won Song, MD, Hyun-Sung Lee, MD, Moon.

Comparison of Thoracoscopic Segmentectomy and Thoracoscopic Lobectomy for Small-Sized Stage IA Lung Cancer Chenxi Zhong, MD, Wentao Fang, MD, Teng Mao,

Split-Course Chemoradiotherapy for Locally Advanced Non-small Cell Lung Cancer: A Single-Institution Experience of 144 Patients Benjamin T. Gielda, MD,

Joshua E. Rosen, BASc, Hari B

Standard Uptake Value Predicts Survival in Non–Small Cell Lung Cancer

Adenocarcinoma in a 40-Year-Old Colonic Interposition Treated With Ivor Lewis Esophagectomy and Esophagogastric Anastomosis David D. Shersher, MD, Edward.

Sarcomatoid Carcinoma of the Lung: A Predictor of Poor Prognosis

Trevor Williams, MD, MPH, Brian C

Defining the Optimal Treatment of Locally Advanced Esophageal Cancer: A Systematic Review and Decision Analysis Andrew J. Graham, MD, MS, Fiona M. Shrive,

Morbidity, Survival, and Site of Recurrence After Mediastinal Lymph-Node Dissection Versus Systematic Sampling After Complete Resection for Non-Small.

Is Sleeve Lobectomy Comparable in Terms of Short- and Long-Term Results With Pneumonectomy After Induction Therapy? A Multicenter Analysis Giacomo Cusumano,

Benjamin E. Lee, MD, Mark Shapiro, MD, John R. Rutledge, MAS, Robert J

Robert E. Merritt, MD, Richard I. Whyte, MD, Nicole T

Video-Assisted Thoracic Surgery Lobectomy: Experience With 1,100 Cases

Tina Cascone, MD, PhD, Kathryn A. Gold, MD, Stephen G

Lobectomy in Octogenarians With Non-Small Cell Lung Cancer: Ramifications of Increasing Life Expectancy and the Benefits of Minimally Invasive Surgery

Establishment of a Multi-Analyte Serum Biomarker Panel to Identify Lymph Node Metastases in Non-small Cell Lung Cancer Jeffrey A. Borgia, PhD, Sanjib.

Clinical T2-T3N0M0 Esophageal Cancer: The Risk of Node Positive Disease Brendon M. Stiles, MD, Farooq Mirza, MD, Anthony Coppolino, MD, Jeffrey L. Port,

Lymph Node Evaluation Achieved by Open Lobectomy Compared With Thoracoscopic Lobectomy for N0 Lung Cancer Robert E. Merritt, MD, Chuong D. Hoang, MD,

Risk Factors for Lymph Node Metastases and Prognosticators of Survival in Patients Undergoing Pulmonary Metastasectomy for Colorectal Cancer Servet Bölükbas,

Surgical Treatment of Metachronous Second Primary Lung Cancer

Philip W. Smith, MD, Hongkun Wang, PhD, Leo M. Gazoni, MD, K

Chris Dickhoff, MD, Max Dahele, MD, PhD, Sayed M

David D. Shersher, MD, Michael S

Conditional Cancer-Specific Versus Cardiovascular-Specific Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer Shawn S. Groth, MD, MS, Natasha.

Asad A. Shah, MD, Mathias Worni, MD, MHS, Christopher R

Dylan R. Nieman, MD, PhD, Christian G. Peyre, MD, Thomas J

Patterns of regional failure in stage III non-small cell lung cancer treated with neoadjuvant chemoradiation therapy and resection Shalini Garg, MD,

Improved Lymph Node Staging in Early-Stage Lung Cancer in the National Cancer Database Seth B. Krantz, MD, Waseem Lutfi, BS, Kristine Kuchta, MS, Chi-Hsiung.

Survival Benefit of Surgery after Chemoradiotherapy for Stage III (N0–2) Non-Small-Cell Lung Cancer Is Dependent on Pathologic Nodal Response Ellis Ziel,

Use of Amiodarone After Major Lung Resection

Elliot Wakeam, MD, MPH, James P. Byrne, MD, Gail E

Outcomes After Extrapleural Pneumonectomy and Intensity-Modulated Radiation Therapy for Malignant Pleural Mesothelioma David C. Rice, MB, BCh, Craig.

Prognostic Significance of Surgical-Pathologic N1 Lymph Node Involvement in Non- Small Cell Lung Cancer Adalet Demir, MD, Akif Turna, MD, PhD, FETCS,

Number of Lymph Nodes Associated With Maximal Reduction of Long-Term Mortality Risk in Pathologic Node-Negative Non–Small Cell Lung Cancer Raymond U.

Survival After Surgery for Pathologic Stage IA Non-Small Cell Lung Cancer Associated With Idiopathic Pulmonary Fibrosis Yuichi Saito, MD, Yasuyuki Kawai,

Recurrence and Survival After Segmentectomy in Patients With Prior Lung Resection for Early-Stage Non-Small Cell Lung Cancer Lisa M. Brown, MD, Brian.

Andrew P. Dhanasopon, MD, Michelle C. Salazar, MD, Jessica R

Circulating Angiogenesis Biomarkers Are Associated With Disease Progression in Lung Adenocarcinoma Shaun Daly, MD, John C. Kubasiak, MD, Daniel Rinewalt,

Video-Assisted Thoracoscopic Surgery is More Favorable Than Thoracotomy for Resection of Clinical Stage I Non-Small Cell Lung Cancer Bryan A. Whitson,

Primary Cardiac Sarcoma

Valerie W Rusch, MD, Ennapadam S Venkatraman, PhD

Importance of Lymph Node Dissection in Thymic Carcinoma

Sublobar Resection Provides an Equivalent Survival After Lobectomy in Elderly Patients With Early Lung Cancer Jiro Okami, MD, PhD, Yuri Ito, PhD, Masahiko.

Impact of Pulmonary Function Measurements on Long-Term Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer Mark F. Berry, MD, Chi-Fu Jeffrey.

Lymph Node Assessment and Impact on Survival in Video-Assisted Thoracoscopic Lobectomy or Segmentectomy Haiyu Zhou, MD, Luis F. Tapias, MD, Henning A.

Radiofrequency Ablation for Stage I Non-Small Cell Lung Cancer: Management of Locoregional Recurrence Michael Lanuti, MD, Amita Sharma, MD, Henning Willers,

Thomas W. Rice, MD, Deepak Khuntia, MD, Lisa A. Rybicki, MS, David J

Number of Metastatic Lymph Nodes in Resected Non–Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD,

Arman Kilic, BS, Matthew J. Schuchert, MD, Brian L

Surgical Techniques and Long-Term Results of Pulmonary Artery Reconstruction in Patients With Lung Cancer Domenico Galetta, MD, PhD, Alessandro Borri,

Shared Decision Making and Effective Risk Communication in the High-Risk Patient With Operable Stage I Non-Small Cell Lung Cancer Pamela Samson, MD,

Resected Synchronous Primary Malignant Lung Tumors: A Population-Based Study Hans Rostad, MD, PhD, Trond-Eirik Strand, MD, Anne Naalsund, MD, Jarle Norstein,

Luis F. Tapias, MD, Douglas J. Mathisen, MD, Cameron D

Preoperative Concurrent Chemoradiotherapy of S-1/Cisplatin for Stage III Non-Small Cell Lung Cancer Masafumi Yamaguchi, MD, PhD, Gouji Toyokawa, MD,

Effect of Formalin Fixation on Tumor Size Determination in Stage I Non-Small Cell Lung Cancer Po-Kuei Hsu, MD, Hsu-Chih Huang, MD, Chih-Cheng Hsieh,

Survival and Outcomes of Pulmonary Resection for Non-Small Cell Lung Cancer in the Elderly: A Nested Case-Control Study Robert J. Cerfolio, MD, Ayesha.

Domenico Galetta, MD, PhD, Lorenzo Spaggiari, MD, PhD

Esophagectomy for T1 Esophageal Cancer: Outcomes in 100 Patients and Implications for Endoscopic Therapy Arjun Pennathur, MD, Andrew Farkas, BA, Alyssa.

Early Surgical Results After Pneumonectomy for Non-Small Cell Lung Cancer are not Affected by Preoperative Radiotherapy and Chemotherapy Tomas Gudbjartsson,

Induction Therapy Followed by Surgery for T3-T4/N0 Non-Small Cell Lung Cancer: Long-Term Results Filippo Lococo, MD, Alfredo Cesario, MD, Stefano Margaritora,

Treating Locally Advanced Disease: An Analysis of Very Large, Hilar Lymph Node Positive Non-Small Cell Lung Cancer Using the National Cancer Data Base

Presentation transcript:

Pneumonectomy After Chemoradiation Therapy for Non-Small Cell Lung Cancer: Does “Side” Really Matter? Anthony W. Kim, MD, L. Penfield Faber, MD, William H. Warren, MD, Sanjib Basu, PhD, Sean C. Wightman, BA, James A. Weber, BA, Philip Bonomi, MD, Michael J. Liptay, MD The Annals of Thoracic Surgery Volume 88, Issue 3, Pages 937-944 (September 2009) DOI: 10.1016/j.athoracsur.2009.04.102 Copyright © 2009 The Society of Thoracic Surgeons Terms and Conditions

Fig 1 The overall 5-year survival for the entire cohort was 33%. The numbers in the parentheses represent the patients at risk. The Annals of Thoracic Surgery 2009 88, 937-944DOI: (10.1016/j.athoracsur.2009.04.102) Copyright © 2009 The Society of Thoracic Surgeons Terms and Conditions

Fig 2 Survival stratified according to right-sided (solid line) and left-sided (dashed line) pneumonectomy demonstrated no statistically significant difference at 5 years. The numbers in the parentheses represent the patients at risk. The Annals of Thoracic Surgery 2009 88, 937-944DOI: (10.1016/j.athoracsur.2009.04.102) Copyright © 2009 The Society of Thoracic Surgeons Terms and Conditions

Fig 3 Survival stratified according to the pathologic stage of complete response (CR, solid line), stage I (small dashed line), stage II (dotted line), stage III (dottted-dashed line), and stage IV (large dashed line). The numbers representing patients at risk were not included for clarity. The Annals of Thoracic Surgery 2009 88, 937-944DOI: (10.1016/j.athoracsur.2009.04.102) Copyright © 2009 The Society of Thoracic Surgeons Terms and Conditions

Fig 4 Survival stratified according to the pathologic lymph node status of N0 (solid line), N1 (dashed line), and N2 (dotted line). The numbers in the parentheses represent the patients at risk. The Annals of Thoracic Surgery 2009 88, 937-944DOI: (10.1016/j.athoracsur.2009.04.102) Copyright © 2009 The Society of Thoracic Surgeons Terms and Conditions

Fig 5 The 5-year survival stratified according to nodal downstaging. Node downstage 0 (solid line) was equivalent to no change in pathologic node status from preoperative staging. Node downstage 1 (dashed line) was equivalent to N2 → N1 or N1 → N0 downstaging. Node downstage 2 (dotted line) was equivalent N2 → N0 downstaging. The numbers in the parentheses represent the patients at risk. The Annals of Thoracic Surgery 2009 88, 937-944DOI: (10.1016/j.athoracsur.2009.04.102) Copyright © 2009 The Society of Thoracic Surgeons Terms and Conditions

Fig 6 Survival stratified according to the development of complications (dashed line) or no complications (solid line). The numbers in the parentheses represent the patients at risk. The Annals of Thoracic Surgery 2009 88, 937-944DOI: (10.1016/j.athoracsur.2009.04.102) Copyright © 2009 The Society of Thoracic Surgeons Terms and Conditions